Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Ovariectomy

Ovariectomy

Ovariectomy is a surgical procedure involving the removal of one or both ovaries.
This procedure may be performed for various reasons, such as the treatment of ovarian cancer, endometriosis, or polycystic ovary syndrome.
The ovaries are important reproductive organs that produce hormones, including estrogen and progesterone.
Ovariectomy can have significant impacts on a person's hormonal balance and overall health.
It is important for researchers studying ovariectomy to identify the most reproducible and accuarate methods from the available literature, pre-prints, and patents to optimize their research outcomes.

Most cited protocols related to «Ovariectomy»

1
Ovarian Mass Surgical Evaluation
Cited 39 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
Biological Assay Biological Markers BLOOD CA-125 Antigen Cyst Diagnosis Ethics Committees, Research Female Castrations Freezing Operative Surgical Procedures Ovarian Cysts Ovariectomy Pathologists Patients Pelvis Physicians Plasma Serum Specimen Collection Tissues Ultrasonography Urine Woman
2
Prospective Surveillance of Lynch Syndrome
Cited 16 times
Each centre had identified each patient to be at increased risk of CRC according to internationally recognised guidelines1 (link)
2 (link) or local adaptations of these. Patients had then been subject to follow-up by colonoscopy and modalities for early detection of endometrial and ovarian cancer, and mutational analysis of the MMR genes. All patients in this study were proven or obligate carriers of pathogenic mutations as judged by the reporting centre in the MLH1, MSH2, MSH6 or PMS2 genes at the time of reporting. EPCAM mutations that lead to methylation of the adjacent MSH2 promoter were included and scored as MSH2 mutations. The mutations were assumed to be germline, regardless of when they were identified. All mutations reported in the 1942 patients were searched for in the Leiden open variant database (LOVD) database (http://chromium.lovd.nl/LOVD2/colon_cancer/) during October 2015: 1310 patients (67%) had pathogenic (class 5) mutations, 28 patients (1%) had probably pathogenic (class 4) mutations and the remaining 604 were not reported in LOVD.
All analysed observations were prospective, commencing when the patients were subjected to their first prospectively planned colonoscopy after being identified as at risk for colon cancer. For the purpose of this report, cases with any cancer prior to or at the same age as first colonoscopy (prevalent cancers) were excluded, as were all cases with <1 year of prospective observation time. This was done to avoid selection bias based on ascertainment and to ensure that no patient had any sign or symptom of cancer at inclusion.
The surveillance guidelines included follow-up aimed at diagnosis of colorectal adenomas or early CRC and in many centres endometrial cancer and ovarian cancer, as well as cancer awareness for all cancers known to be associated with LS. Surveillance and management guidelines have changed over time, and collaborating centres were subject to local/national decisions on how to practise at different times. None of these variations were used as variables in the present study. A detailed, referenced description of follow-up and compliance is provided in online supplementary table S2. The table and the references included there show that from the outset the reporting centres used different intervals between colonoscopies, but that from around 1996 onwards all except for the Finnish centre followed the emerging international guidelines advocating a 2-year interval or less. Intervals between gynaecological examinations were in general shorter. As previously published in the references given in the table, all visible adenomas at colonoscopies were removed. The references also show that precursor lesions were less frequently found in the endometrium or ovaries. In short, secondary prevention of colon cancer by identifying and removing precursor/early lesions was found to be promising, while this was not the case for endometrial and ovarian cancer. In consequence, all centres continued the colonoscopic surveillance, while some advised prophylactic hysterectomy and oophorectomy to prevent gynaecological cancers. All patients reported to the database had complete data sets, and there were no missing values.
Some centres had previously reported the observed incidence of cancer in their series but with different methods to those used in this report.3–11 (link) One group had reported previously on survival.4 (link) The intention of this report was to compile all information available on prospectively observed outcomes in LS patients without previous cancer and patients who were previously reported are included in the current report.
Møller P., Seppälä T., Bernstein I., Holinski-Feder E., Sala P., Evans D.G., Lindblom A., Macrae F., Blanco I., Sijmons R., Jeffries J., Vasen H., Burn J., Nakken S., Hovig E., Rødland E.A., Tharmaratnam K., de Vos tot Nederveen Cappel W.H., Hill J., Wijnen J., Green K., Lalloo F., Sunde L., Mints M., Bertario L., Pineda M., Navarro M., Morak M., Renkonen-Sinisalo L., Frayling I.M., Plazzer J.P., Pylvanainen K., Sampson J.R., Capella G., Mecklin J.P, & Möslein G. (2015). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 66(3), 464-472.
Publication 2015
Acclimatization Adenoma Awareness Cancer of Colon Chromium Colonoscopy Condoms Diagnosis Early Diagnosis Endometrial Carcinoma Endometrium Genes Germ Line Gynecological Examination Hysterectomy Malignant Neoplasms Methylation MLH1 protein, human MSH6 protein, human Mutation Ovarian Cancer Ovariectomy Ovary pathogenesis Patients PMS2 protein, human Secondary Prevention TACSTD1 protein, human
3
BRCA1 Mutation Carriers Cohort Study
Cited 15 times

BRCA1 mutation carriers were recruited by 45 study centers in 25 countries through CIMBA. The majority were recruited through cancer genetics clinics, and enrolled into national or regional studies. The remainder were identified by population-based sampling or community recruitment. Eligibility for CIMBA association studies was restricted to female carriers of pathogenic BRCA1 mutations age 18 years or older at recruitment. Information collected included year of birth, mutation description, self-reported ethnic ancestry, age at last follow-up, ages at breast or ovarian cancer diagnoses, and age at bilateral prophylactic mastectomy and oophorectomy. Information on tumour characteristics, including ER-status of the breast cancers, was also collected. Related individuals were identified through a unique family identifier. Women were included in the analysis if they carried mutations that were pathogenic according to generally recognized criteria.
Couch F.J., Wang X., McGuffog L., Lee A., Olswold C., Kuchenbaecker K.B., Soucy P., Fredericksen Z., Barrowdale D., Dennis J., Gaudet M.M., Dicks E., Kosel M., Healey S., Sinilnikova O.M., Lee A., Bacot F., Vincent D., Hogervorst F.B., Peock S., Stoppa-Lyonnet D., Jakubowska A., Investigators K., Radice P., Schmutzler R.K., Domchek S.M., Piedmonte M., Singer C.F., Friedman E., Thomassen M., Hansen T.V., Neuhausen S.L., Szabo C.I., Blanco I., Greene M.H., Karlan B.Y., Garber J., Phelan C.M., Weitzel J.N., Montagna M., Olah E., Andrulis I.L., Godwin A.K., Yannoukakos D., Goldgar D.E., Caldes T., Nevanlinna H., Osorio A., Terry M.B., Daly M.B., van Rensburg E.J., Hamann U., Ramus S.J., Ewart Toland A., Caligo M.A., Olopade O.I., Tung N., Claes K., Beattie M.S., Southey M.C., Imyanitov E.N., Tischkowitz M., Janavicius R., John E.M., Kwong A., Diez O., Balmaña J., Barkardottir R.B., Arun B.K., Rennert G., Teo S.H., Ganz P.A., Campbell I., van der Hout A.H., van Deurzen C.H., Seynaeve C., Gómez Garcia E.B., van Leeuwen F.E., Meijers-Heijboer H.E., Gille J.J., Ausems M.G., Blok M.J., Ligtenberg M.J., Rookus M.A., Devilee P., Verhoef S., van Os T.A., Wijnen J.T., Frost D., Ellis S., Fineberg E., Platte R., Evans D.G., Izatt L., Eeles R.A., Adlard J., Eccles D.M., Cook J., Brewer C., Douglas F., Hodgson S., Morrison P.J., Side L.E., Donaldson A., Houghton C., Rogers M.T., Dorkins H., Eason J., Gregory H., McCann E., Murray A., Calender A., Hardouin A., Berthet P., Delnatte C., Nogues C., Lasset C., Houdayer C., Leroux D., Rouleau E., Prieur F., Damiola F., Sobol H., Coupier I., Venat-Bouvet L., Castera L., Gauthier-Villars M., Léoné M., Pujol P., Mazoyer S., Bignon Y.J., Złowocka-Perłowska E., Gronwald J., Lubinski J., Durda K., Jaworska K., Huzarski T., Spurdle A.B., Viel A., Peissel B., Bonanni B., Melloni G., Ottini L., Papi L., Varesco L., Tibiletti M.G., Peterlongo P., Volorio S., Manoukian S., Pensotti V., Arnold N., Engel C., Deissler H., Gadzicki D., Gehrig A., Kast K., Rhiem K., Meindl A., Niederacher D., Ditsch N., Plendl H., Preisler-Adams S., Engert S., Sutter C., Varon-Mateeva R., Wappenschmidt B., Weber B.H., Arver B., Stenmark-Askmalm M., Loman N., Rosenquist R., Einbeigi Z., Nathanson K.L., Rebbeck T.R., Blank S.V., Cohn D.E., Rodriguez G.C., Small L., Friedlander M., Bae-Jump V.L., Fink-Retter A., Rappaport C., Gschwantler-Kaulich D., Pfeiler G., Tea M.K., Lindor N.M., Kaufman B., Shimon Paluch S., Laitman Y., Skytte A.B., Gerdes A.M., Pedersen I.S., Moeller S.T., Kruse T.A., Jensen U.B., Vijai J., Sarrel K., Robson M., Kauff N., Mulligan A.M., Glendon G., Ozcelik H., Ejlertsen B., Nielsen F.C., Jønson L., Andersen M.K., Ding Y.C., Steele L., Foretova L., Teulé A., Lazaro C., Brunet J., Pujana M.A., Mai P.L., Loud J.T., Walsh C., Lester J., Orsulic S., Narod S.A., Herzog J., Sand S.R., Tognazzo S., Agata S., Vaszko T., Weaver J., Stavropoulou A.V., Buys S.S., Romero A., de la Hoya M., Aittomäki K., Muranen T.A., Duran M., Chung W.K., Lasa A., Dorfling C.M., Miron A., Benitez J., Senter L., Huo D., Chan S.B., Sokolenko A.P., Chiquette J., Tihomirova L., Friebel T.M., Agnarsson B.A., Lu K.H., Lejbkowicz F., James P.A., Hall P., Dunning A.M., Tessier D., Cunningham J., Slager S.L., Wang C., Hart S., Stevens K., Simard J., Pastinen T., Pankratz V.S., Offit K., Easton D.F., Chenevix-Trench G, & Antoniou A.C. (2013). Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 9(3), e1003212.
Publication 2013
BRCA1 protein, human Breast Childbirth Diagnosis Eligibility Determination Gene, Cancer Malignant Neoplasm of Breast Mutation Neoplasms Ovarian Cancer Ovariectomy pathogenesis Prophylactic Mastectomy Woman
4
BMI and Breast Cancer Risk by Subtype
Cited 15 times
We used the polytomous model and the joint Cox model to formally compare the association of BMI with breast cancer by ER and PR status using data from the NIH-AARP Diet and Health Study. The NIH-AARP study was established in 1995 when a baseline screening questionnaire that queried information on medical history and lifestyle characteristics was returned by 566,398 AARP (formerly known as the American Association of Retired Persons) members. Participants were aged 50–71 and resided in 1 of 6 US States (California, Florida, Louisiana, New Jersey, North Carolina and Pennsylvania) or two metropolitan areas (Atlanta, Georgia, and Detroit, Michigan), selected because they were known to have high-quality cancer registries and a large AARP membership (18 (link)).
A total of 54,629 women remained in the analytic cohort after exclusion of pre-menopausal women, women with previous history of cancer as well as current users of hormone therapy and women residing in Florida or Pennsylvania because these two states have substantial proportion of participants with missing ER/PR data. In this cohort, 1,492 cases were diagnosed with breast cancer with known ER/PR status obtained from cancer registry records, in which 246 were classified as ER−/PR− breast cancer cases (16.5%), 231 ER+/PR− cases (15.5%), 18 ER−/PR+ cases (0.01%) and 997 ER+/PR+ cases (66.8%). Body mass index (BMI; kg/m2) was derived from self-reported height and weight on the baseline survey. In statistical models, BMI was expressed as categorical variables (<25.0 kg/m2; 25.0–29.9 kg/m2; ≥30.0 kg/m2). Covariates included in the multivariable models were consistent with those reported in the prior analysis by Ahn et al (18 (link)), namely age, race or ethnic, family history of breast cancer, level of education, age at menarche, age at menopause, age at first birth, parity, smoking status, physical activity, fat intake, alcohol consumption, oophorectomy, and height. The HRs for the association of BMI with the four breast cancer subtypes were estimated simultaneously and the difference in HRs were assessed. The analysis was conducted using SAS 9.2 (SAS Institute, Cary NC).
Xue X., Kim M.Y., Gaudet M.M., Park Y., Heo M., Hollenbeck A.R., Strickler H.D, & Gunter M.J. (2013). A Comparison of the Polytomous Logistic Regression and Joint Cox Proportional Hazards Models for Evaluating Multiple Disease Subtypes in Prospective Cohort Studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22(2), 275-285.
Publication 2012
Breast Cancer, Familial Diet Hormones Index, Body Mass Joints Malignant Neoplasm of Breast Malignant Neoplasms Menarche Ovariectomy Premenopause Therapeutics Woman
5
MCAO Stroke Model in Aged Mice
Cited 14 times
Focal transient cerebral ischemia was induced by MCAO (0.21mm silicone coated suture) for 90 minutes followed by reperfusion as described previously (McCullough et al. 2005 (link)). In aging mice a larger 0.23mm silicone coated suture was utilized to achieve occlusion. Sham animals were subjected to sutures of the same size but the suture was not advanced into the middle cerebral artery. Cerebral blood flow (CBF) was measured by laser Doppler flowmetry (LDF, Moor Instruments Ltd, England) during the surgery as previously described (McCullough et al. 2005 (link)). Only the mice in which CBF in MCA area showed a sharp drop of over 85% of control immediately after MCA occlusion were included.
Neurological deficit was confirmed and scored as follows: 0, no deficit; 1, forelimb weakness and torso turning to the ipsilateral side when held by tail; 2, circling to affected side; 3, unable to bear weight on affected side; and 4, no spontaneous locomotor activity or barrel rolling. Monitoring of physiological variables was performed in companion cohorts for all groups prior to MCAO and 60 minutes after reperfusion as described previously (McCullough et al. 2005 (link)).
In ovariectomized (Ovx) females the ovaries were surgically removed 10 days prior to MCAO as described previously (McCullough et al. 2005 (link)). In E2 treated mice 17β-estradiol was delivered by subcutaneous SILASTIC capsule (0.062 inch inner diameter; 0.125 inch outer diameter) filled with 0.035 ml of 17β-estradiol (180μg/ml; Sigma) (McCullough et al. 2005 (link)) in sesame oil implanted at the time of ovariectomy. Serum 17β-estradiol and levels of the inflammatory marker IL-6 was measured in each group by ELISA (E2: IBL HAMBURG, Hamburg, Germany; IL-6: eBioscience, San Diego, CA). Uteruses of female mice were also weighed at sacrifice to confirm end-organ estrogen effects and ELISA values.
Liu F., Yuan R., Benashski S.E, & McCullough L.D. (2009). Changes in experimental stroke outcome across the lifespan. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 29(4), 792-802.
Publication 2009
Animals ARID1A protein, human Bears Capsule Cerebrovascular Circulation Dental Occlusion Enzyme-Linked Immunosorbent Assay Estradiol Females Inflammation Laser-Doppler Flowmetry Locomotion Mus Operative Surgical Procedures Ovariectomy Ovary Pets Reperfusion Serum Sesame Oil Silastic Silicones Sutures Tail Torso Transient Cerebral Ischemia Upper Extremity Paresis Uterus

Most recents protocols related to «Ovariectomy»

1
Generating OVX Mouse Model

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Biological Assay Female Castrations Mice, House Mice, Inbred C57BL Operative Surgical Procedures Ovariectomy Woman
2
Ovariectomy-Induced Vaginal Atrophy Model
Female BALB/c mice (8 weeks; n=30) were maintained on a standard diet and then fasted overnight before the experiment. The mice were divided into control and experimental groups, and the experimental group was anesthetized, a midline abdominal incision was made, both ovaries were removed, and the abdomen was sutured. The mice were treated with intramuscular antibiotics for 2 days to prevent infection. Two weeks after the surgery, serum estradiol levels were measured by enzyme-linked immunosorbent assay in mice in the control and experimental groups. The experimental group was further divided into an ovariectomy group, an HA-C18 vehicle group, and an HA-C18-RA group. The HA-C18 vehicle group and HA-C18-RA group were administered an emulsion type of HA-C18 vehicle (2.5 µg/mouse) and HA-C18-RA (2.5 µg/mouse) intravaginally once daily for 4 weeks, respectively.
After 4 weeks of treatment, murine vaginal tissue was removed and dissected to make a cryosection for histologic examination, immunohistochemistry, and Western blot. Sections of the vagina were stained with hematoxylin and eosin (H&E) to evaluate vaginal epithelial layers.
Kim T., Chung H.S., Lee H.S., Uthaman S., Park I.K, & Park K. (2023). Effects of retinoid-loaded hyaluronic acid nanomicelles on vaginal epithelium in a murine menopause model. Investigative and Clinical Urology, 64(2), 182-188.
Publication 2023
Abdomen Abdominal Cavity Aftercare Antibiotics, Antitubercular Cryoultramicrotomy Diet Emulsions Enzyme-Linked Immunosorbent Assay Eosin Estradiol Immunohistochemistry Infection Mice, House Mice, Inbred BALB C Mus Operative Surgical Procedures Ovariectomy Ovary Serum Tissues Vagina Western Blotting Woman
3
Eligibility Criteria for Early-Stage Endometrial Cancer
1. Age of 18–75 years
2. Preoperative radiographic assessment including pelvic magnetic resonance imaging or abdominal computerized tomography (CT) is performed to determine tumor is confined to uterus including cervical involvement. Preoperative histology indicates EEC.
3. A history of surgery with curative intent, including total abdominal or laparoscopic hysterectomy, bilateral salpingectomy with or without oophorectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection, with or without para-aortic lymphadenectomy
4. Primary histologically confirmed EEC, with one of the following combinations:
1. Eastern Cooperative Oncology Group performance status of 0 or 1
2. Adequate systemic organ function, as follows:
3. Signed, written informed consent
Li Y., Zhu C., Xie H., Chen Y., Lv W., Xie X, & Wang X. (2023). Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of Gynecologic Oncology, 34(2), e37.
Publication 2023
Abdomen Aorta Dissection Hysterectomy Laparoscopy Lymph Node Excision Neck Neoplasms Operative Surgical Procedures Ovariectomy Pelvis Radiography Salpingectomy Sentinel Lymph Node Uterus X-Ray Computed Tomography
4
Gynecologic Treatments for Uterine Fibroids
Descriptive statistics were used to summarize study population characteristics. Treatment patterns over the first and second years following the index date, and for the full duration of postindex follow-up, were assessed as the proportion of patients treated with gynecologic procedures and/or prescribed pharmacologic therapies of interest that were reimbursed by insurance. Pharmacologic therapies of interest were hormonal treatments (oral and nonoral contraceptives), including intrauterine devices (IUDs, except ParaGard®/copper IUD), estrogen, progestin, aromatase inhibitors, elagolix, danazol, leuprolide, or any luteinizing hormone-releasing hormone agonists.
Also evaluated were the use of tranexamic acid and pain medicines, including narcotic (prescribed for ≥30 days) and prescription non-narcotic analgesics. Not available for analysis were over-the-counter products not captured in medical claims and prescriptions not reimbursed by the payer. Gynecologic procedures of interest were hysterectomy, operative laparoscopy, myomectomy, oophorectomy, ablation of the endometrium and/or fibroids, excision, and salpingectomy. Finally, data were collected for pharmacologic treatments of interest (hormonal or analgesic) received by patients in the year preceding the index date.
Patients in both cohorts who underwent hysterectomy within 1 year postindex date were further stratified by age. Logistic regression models were constructed to determine factors associated with specific treatments (hysterectomy and hormonal therapy) in patients with UF-HMB and UF-only. To isolate these findings to patients who received hysterectomy due to UF, the regression analysis excluded patients with a claim for endometriosis (ICD-9 617.X or ICD-10 N80.X). This exclusion was applied because of the potential for confounding due to concomitant comorbidity. The variables included in the logistic regression were factors that could contribute to treatment decision-making and that could be captured in claims data. These were age, abnormal bleeding, anemia, fatigue, infertility, pain, prior- and post-UF diagnosis use of medications, including hormonal treatment, non-narcotic, or narcotic analgesic treatment, and inpatient or outpatient diagnosis site. Data were analyzed using SAS/STAT(r) software, version 15.1 (2016 SAS Institute Inc., Cary, NC, USA).
McKain L., Edsall K., Dufour R, & Lickert C. (2023). Treatment Patterns in Patients with Uterine Fibroids With and Without a Diagnosis of Heavy Menstrual Bleeding: Results from a Large U.S. Claims Database. Journal of Women's Health, 32(3), 332-340.
Publication 2023
agonists Analgesics Analgesics, Non-Narcotic Anemia Aromatase Inhibitors Contraceptive Agents Danazol Diagnosis Drugs, Non-Prescription elagolix Endometrial Ablation Techniques Endometriosis Estrogens Fatigue Gonadorelin Hysterectomy Inpatient Intrauterine Devices Intrauterine Devices, Copper Laparoscopy Leuprolide Narcotic Analgesics Narcotics Outpatients Ovariectomy Pain Patients Pharmaceutical Preparations Pharmacotherapy Prescriptions Progestins Salpingectomy Sterility, Reproductive Tranexamic Acid Uterine Fibroids Uterine Myomectomy
5
Premature Ovarian Failure in FMR1 Mice
All animal procedures were performed with the approval from the University of California (Riverside, CA) Animal Care and Use Committee and in accordance with the National Institutes of Health Animal care and Use Guidelines. Breeding pairs of FVB.129P2-Fmr1tm1Cgr/J (Fmr1 KO) and their congenic controls (WT) mice were obtained from Jackson Laboratories and bred in-house. Mice were maintained under a 12-h light, 12-h dark cycle and received food and water ad libitum. Since we were interested in determining the mechanisms of premature ovarian failure in women with mutations in the FMR1 gene, only female mice were used for our studies. Estrous cycle stage was determined with vaginal smears and females were collected in a specific estrous cycle stage, as indicated for each analysis. For fertility studies, Fmr1 KO females and WT controls were housed with WT males and their litters and numbers of pups per litter were recorded. Ovariectomy was performed, as described before, using 8-week-old mice (43 (link)). Animals were allowed to recover and seven days later blood was collected for hormone analyses as described below.
Villa P.A., Lainez N.M., Jonak C.R., Berlin S.C., Ethell I.M, & Coss D. (2023). Altered GnRH neuron and ovarian innervation characterize reproductive dysfunction linked to the Fragile X messenger ribonucleoprotein (Fmr1) gene mutation. Frontiers in Endocrinology, 14, 1129534.
Publication 2023
Animals BLOOD Estrous Cycle Females Fertility Food Genes Hormones Light Males Mice, House Mutation Ovarian Failure, Premature Ovariectomy Patient Holding Stretchers Vaginal Smears Woman

Top products related to «Ovariectomy»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
17β estradiol by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Sao Tome and Principe, China, France, Macao, Switzerland, Israel, Belgium, Hungary, Canada, Italy
17β-estradiol is a natural estrogen hormone produced by the ovaries, adrenal glands, and other tissues in the body. It is a key component in various laboratory and research applications, serving as a substrate, reference standard, or analytical tool for the study of estrogen-related processes and pathways.
3
Rompun by Bayer
Sourced in Germany, France, United States, United Kingdom, Canada, Italy, Brazil, Belgium, Cameroon, Switzerland, Spain, Australia, Ireland, Sweden, Portugal, Netherlands, Austria, Denmark, New Zealand
Rompun is a veterinary drug used as a sedative and analgesic for animals. It contains the active ingredient xylazine hydrochloride. Rompun is designed to induce a state of sedation and pain relief in animals during medical procedures or transportation.
4
Sprague dawley rat by Charles River Laboratories
Sourced in United States, China, Germany, Canada, United Kingdom, Japan, France, Italy, Morocco, Hungary, New Caledonia, Montenegro, India
Sprague-Dawley rats are an outbred albino rat strain commonly used in laboratory research. They are characterized by their calm temperament and reliable reproductive performance.
5
Progesterone by Merck Group
Sourced in United States, Germany, United Kingdom, Canada, France, Sao Tome and Principe, Macao, Japan, Italy, Brazil, China, Netherlands
Progesterone is a steroid hormone that plays a crucial role in the female reproductive system. It is a key component in the regulation of the menstrual cycle and supports the maintenance of pregnancy. Progesterone is commonly used in various lab equipment and scientific research applications.
6
C57bl 6 mice by Charles River Laboratories
Sourced in China, United States, Germany, United Kingdom, Canada, Japan, France, Italy, Morocco, Spain, Netherlands, Montenegro, Belgium, Portugal, Ireland, Hungary
The C57BL/6 mouse is a widely used inbred mouse strain. It is a common laboratory mouse model utilized for a variety of research applications.
7
C57bl 6 mice by Jackson ImmunoResearch
Sourced in United States, Montenegro, Canada, China, France, United Kingdom, Japan, Germany
C57BL/6 mice are a widely used inbred mouse strain commonly used in biomedical research. They are known for their black coat color and are a popular model organism due to their well-characterized genetic and physiological traits.
8
Streptomycin by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, China, Macao, Poland, Switzerland, Spain, Sao Tome and Principe, Japan, Brazil, Canada, Australia, Belgium, Austria, Netherlands, Israel, India, Sweden, Denmark, Ireland, Czechia, Norway, Gabon, Argentina, Portugal, Hungary, Holy See (Vatican City State), Mexico, Ukraine, Slovakia
Streptomycin is a laboratory product manufactured by Merck Group. It is an antibiotic used in research applications.
9
Sesame oil by Merck Group
Sourced in United States, India, Germany, Japan, United Kingdom
Sesame oil is a versatile laboratory product that serves as a carrier or base oil in various applications. It is a natural, vegetable-derived oil that is commonly used in scientific and industrial settings. Sesame oil has a range of physical and chemical properties that make it suitable for use in lab equipment and procedures. However, a detailed description of its specific functions and intended uses would require further research to maintain an unbiased and factual approach.
10
Wistar rat by Charles River Laboratories
Sourced in United States, Germany, China, United Kingdom, Japan, France, Canada, Italy, Spain, Hungary, Belgium, Denmark
Wistar rats are a commonly used strain of laboratory rats. They are characterized by their wide, rounded body shape and are known for their reliable and consistent performance in various research applications.

More about "Ovariectomy"

Ovariectomy, also known as oophorectomy, is a surgical procedure that involves the removal of one or both ovaries.
This procedure is commonly performed to treat various conditions, such as ovarian cancer, endometriosis, or polycystic ovary syndrome (PCOS).
The ovaries are essential reproductive organs that produce important hormones, including estrogen and progesterone, which play a crucial role in a person's overall health and well-being.
Researchers studying ovariectomy may utilize various animal models, such as Sprague-Dawley rats, C57BL/6 mice, and Wistar rats, to investigate the impacts of ovarian hormone depletion on different physiological and behavioral outcomes.
These animal studies often involve the administration of substances like 17β-estradiol, progesterone, and Rompun (xylazine) to study the effects of hormone replacement or modulation.
It is important for researchers to identify the most reproducible and accurate methods from the available literature, pre-prints, and patents to optimize their research outcomes.
PubCompare.ai, an AI-driven platform, can assist researchers in this process by providing comprehensive comparisons of different protocols and identifying the most suitable approaches for their ovariectomy studies.
Furthermore, researchers may need to consider factors such as the use of antibiotics like streptomycin and the choice of vehicle (e.g., sesame oil) when designing their experimental protocols.
By leveraging the insights and tools provided by platforms like PubCompare.ai, researchers can enhance the quality and reliability of their ovariectomy research, ultimately contributing to a better understanding of the physiological and hormonal implications of this surgical intervention.